# Clusterin in disease pathology

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/clusterin-in-disease-pathology/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers explores the multifaceted role of Clusterin, a chaperone protein, in cancer development, progression, and therapy. It investigates its involvement in apoptosis inhibition, TGF-ß signaling modulation, angiogenesis promotion, chemoresistance, and its potential as a biomarker for various cancers. The papers also discuss the implications of Clusterin in metastasis, particularly in prostate cancer. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t14364 |
| Works | 37 |

## Topic papers all

Showing 15 of 37.

- [Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group](https://scholariq.org/papers/eligibility-and-response-guidelines-for-phase-ii-clinical-trials-in-androgen/)
- [Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer](https://scholariq.org/papers/association-between-braf-v600e-mutation-and-mortality-in-patients-with-papillary/)
- [Gene Expression Alterations in Prostate Cancer Predicting Tumor Aggression and Preceding Development of Malignancy](https://scholariq.org/papers/gene-expression-alterations-in-prostate-cancer-predicting-tumor-aggression-and/)
- [Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-the-report-of-the-advanced/)
- [Association Between <i>BRAF</i> V600E Mutation and Recurrence of Papillary Thyroid Cancer](https://scholariq.org/papers/association-between-i-braf-i-v600e-mutation-and-recurrence-of-papillary-thyroid/)
- [Safety and Benefit of Discontinuing Statin Therapy in the Setting of Advanced, Life-Limiting Illness](https://scholariq.org/papers/safety-and-benefit-of-discontinuing-statin-therapy-in-the-setting-of-advanced/)
- [Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study](https://scholariq.org/papers/prostate-cancer-screening-in-men-aged-50-69-years-sthlm3-a-prospective/)
- [Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy](https://scholariq.org/papers/associations-of-luminal-and-basal-subtyping-of-prostate-cancer-with-prognosis/)
- [Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis](https://scholariq.org/papers/serum-leucine-rich-alpha-2-glycoprotein-is-a-disease-activity-biomarker-in/)
- [iTRAQ-based proteomic identification of leucine-rich α-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases](https://scholariq.org/papers/itraq-based-proteomic-identification-of-leucine-rich-2-glycoprotein-as-a-novel/)
- [High-Density Lipoprotein Stimulates Endothelial Cell Migration and Survival Through Sphingosine 1-Phosphate and Its Receptors](https://scholariq.org/papers/high-density-lipoprotein-stimulates-endothelial-cell-migration-and-survival/)
- [Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection](https://scholariq.org/papers/lead-time-trajectory-of-ca19-9-as-an-anchor-marker-for-pancreatic-cancer-early/)
- [Prognostic effects of <i>TERT</i> promoter mutations are enhanced by coexistence with <i>BRAF</i> or <i>RAS</i> mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients](https://scholariq.org/papers/prognostic-effects-of-i-tert-i-promoter-mutations-are-enhanced-by-coexistence/)
- [The APEX Quantitative Proteomics Tool: Generating protein quantitation estimates from LC-MS/MS proteomics results](https://scholariq.org/papers/the-apex-quantitative-proteomics-tool-generating-protein-quantitation-estimates/)
- [Biochemical recurrence after radical prostatectomy: what does it mean?](https://scholariq.org/papers/biochemical-recurrence-after-radical-prostatectomy-what-does-it-mean/)

## Topic primary papers

- [Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis](https://scholariq.org/papers/serum-leucine-rich-alpha-2-glycoprotein-is-a-disease-activity-biomarker-in/)
- [iTRAQ-based proteomic identification of leucine-rich α-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases](https://scholariq.org/papers/itraq-based-proteomic-identification-of-leucine-rich-2-glycoprotein-as-a-novel/)
- [Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis](https://scholariq.org/papers/leucine-rich-alpha-2-glycoprotein-is-a-serum-biomarker-of-mucosal-healing-in/)
- [Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease](https://scholariq.org/papers/leucine-rich-alpha-2-glycoprotein-as-a-marker-of-mucosal-healing-in-inflammatory/)
- [Temperature-Sensitive Polymer-Coated Magnetic Nanoparticles as a Potential Drug Delivery System for Targeted Therapy of Thyroid Cancer](https://scholariq.org/papers/temperature-sensitive-polymer-coated-magnetic-nanoparticles-as-a-potential-drug/)
- [LRP1b shows restricted expression in human tissues and binds to several extracellular ligands, including fibrinogen and apoE – carrying lipoproteins](https://scholariq.org/papers/lrp1b-shows-restricted-expression-in-human-tissues-and-binds-to-several/)
- [Procalcitonin as a marker of medullary thyroid carcinoma](https://scholariq.org/papers/procalcitonin-as-a-marker-of-medullary-thyroid-carcinoma/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.